Roxana Dronca

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Immunology, Oncology +17

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +17

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas, Omid Hamid, Adil Daud et al. · JAMA · 2016 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Omid Hamid, Caroline Robert, Adil Daud et al. · Annals of Oncology · 2019 · 944 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford et al. · Journal of Clinical Oncology · 2016 · 751 citations · Full text

Medicine, Clinical Sciences, Oncology +16